A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer
Study of Select Immunotherapy Combinations in Patients with Triple Negative Breast Cancer
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAS1826
U.S. Govt. ID: NCT03742349
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to identify the doses of spartalizumab (PDR001) with LAG525 in combination with either NIR178, capmatinib (INC280), MCS110 or canakinumab (ACZ885) that can be given safely. The study will also test how well spartalizumab (PDR001) with LAG525 in combination with either NIR178, capmatinib (INC280), MCS110 or canakinumab (ACZ885) might work in treating patients with TNBC.
This study is closed
Investigator
Meghna Trivedi, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with breast cancer? Yes No
Have you had no more than 2 prior treatments for breast cancer? Yes No
Are you willing to possibly undergo additional biopsies? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE